Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: Efficacy, tolerability, viral kinetics and cytokine response

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 9, 2010, Pages 1018-1027

  Rotman, Y ^a   Borg, B B ^a   Soza, A ^a,b   Feld, J J ^a   Modi, A A ^a   Loomba, R ^a   Lutchman, G ^a   Rivera, E ^a   Doo, E ^a   Ghany, M G ^a   Heller, T ^a   Neumann, A U ^c   Liang, T J ^a   Hoofnagle, J H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INDUCIBLE PROTEIN 10; PEGINTERFERON ALPHA2A; POLO LIKE KINASE 2; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; MESSENGER RNA; RECOMBINANT PROTEIN;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD TOXICITY; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RESPONSE; DEPRESSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LOW DRUG DOSE; MALE; MICROBIAL KINETICS; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; DRUG COMBINATION; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 77950593069     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04263.x     Document Type: Article

References (30)

1. Perz JF, Farrington LA, Pecoraro C, Hutin YJ, Armstrong GL. Estimated global prevalence of hepatitis C virus infection. Annual Meeting of the Infectious Diseases Society of America.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 45 : 529 538.
3. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007 42 : 513 521. (Pubitemid 47190067)
4. Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 1999 3 : 693 716. (Pubitemid 29450464)
5. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
6. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 357 : 124 134. (Pubitemid 47057730)
7. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008 28 : 397 404. (Pubitemid 352033287)
8. Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004 99 : 1298 1305. (Pubitemid 39062267)
9. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001 34 : 395 403. (Pubitemid 32702353)
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965. (Pubitemid 32913521)
11. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- therapy. Science 1998 282 : 103 107. (Pubitemid 28471138)
12. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005 128 : 1437 1444. (Pubitemid 40712193)
13. Taylor MW, Tsukahara T, Brodsky L, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007 81 : 3391 3401. (Pubitemid 46456648)
14. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008 105 : 7034 7039. (Pubitemid 351754525)
15. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007 46 : 1548 1563. (Pubitemid 350155537)
16. Diago M, Castellano G, Garcia-Samaniego J, et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006 55 : 374 379. (Pubitemid 43268277)
17. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006 44 : 1617 1625. (Pubitemid 44953667)
18. Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006 194 : 895 903. (Pubitemid 44454074)
19. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977 1 : 385 401.
20. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001 120 : 1438 1447. (Pubitemid 32322318)
21. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2 × 2 tables. Biometrics 1977 33 : 593 602. (Pubitemid 8236330)
22. Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol 2007 46 : 947 954. (Pubitemid 46546604)
23. Feld JJ, Ko MS, Hara K, et al. Ribavirin improves second phase kinetics through enhanced interferon signaling in genotype 1 HCV infection. AASLD Liver Meeting
24. Sood A, Midha V, Hissar S, et al. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol 2008 23 : 203 207. (Pubitemid 351257668)
25. Meyer-Wyss B, Rich P, Egger H, et al. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 2006 13 : 457 465. (Pubitemid 43911755)
26. Krawitt EL, Gordon SR, Grace ND, et al. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2006 101 : 1268 1273. (Pubitemid 43829993)
27. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001 33 : 433 438.
28. Abergel A, Hezode C, Leroy V, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat 2006 13 : 811 820. (Pubitemid 44748285)
29. Weiland O, Hollander A, Mattsson L, et al. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008 15 : 641 645.
30. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002 35 : 930 936. (Pubitemid 34258389)